Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dectin-1 is a C-type lectin receptor primarily expressed on myeloid cells (macrophages, dendritic cells, neutrophils). It recognizes fungal β-glucans and triggers innate immune responses by recruiting Syk following ligand-induced receptor clustering and hemITAM phosphorylation. This initiates a signaling cascade culminating in NF-κB activation, driving expression of pro-inflammatory cytokines, chemokines, and reactive oxygen species. In addition to antifungal immunity, Dectin-1 signaling shapes adaptive immunity (Th1/Th17 skewing), acts in trained immunity, and has emerging roles in cancer and inflammatory diseases. Syk and NF-κB are integral downstream mediators in this pathway, but Dectin-1 is the primary molecular target for therapeutic intervention in the pathway.
Agonists: Activate Dectin-1, leading to Syk recruitment, phosphorylation, and downstream immune signaling (cytokine release, phagocytosis, trained immunity) Antagonists (hypothetical/in development): Block ligand binding, inhibit Syk recruitment and NF-κB activation
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dendritic cell-associated C-type lectin-1 receptor (Dectin-1).